Nausea profile of amylin analogues compared with GLP-1 agonists posts 61–77

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

Post #61 answers the question as asked. The question underneath it is different.

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

Worth separating two things that post #61 runs together.

Having read the whole nausea profile of amylin analogues thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.

An honest declaration on nausea profile of amylin analogues: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.

On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area percent cannot see what stays on the column.

I have no interest in any supplier named above.

For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.

Worth separating two things that post #65 runs together.

Nausea profile of amylin analogues is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.

This follows post #65 rather than contradicting it.

Trying to state the nausea profile of amylin analogues position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.

Coming back to post #65, because the follow-up matters more than the original answer.

Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.

Old habit: I write down the expected answer before I calculate it.

Adding a small correction to the nausea profile of amylin analogues summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.

Post #68 is right about the mechanism and I think understates the practical bit.

Before the thread moves on from nausea profile of amylin analogues — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

The step people skip is the one I have spelled out.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

The conclusion is tentative; the arithmetic underneath it is not.

Right — I had this wrong and I am glad to have read it before it mattered.